Clinical Research in Infectious Diseases (CRID)
EMMES serves as the Statistical and Data Coordinating Center (SDCC) for Clinical Research in Infectious Diseases (CRID) for more than 100 vaccine and infectious disease protocols sponsored by the National Institute of Allergy and Infectious Diseases’ (NIAID) Division of Microbiology and Infectious Diseases (DMID).
The CRID project supports a broad range of DMID’s clinical research, including single-site and multi-center, domestic and international, Phase 1-4 clinical trials of bacterial, viral, and parasitic vaccines, therapeutics, and other biologics and drugs as preventive and therapeutic measures against infectious diseases in people of all ages and risk categories. This contract includes targeted surveillance for pathogens of interest; evaluations of novel investigational product delivery systems; and re-evaluation of current vaccine formulations, schedules, and modes of delivery. CRID studies also evaluate the safety and efficacy of vaccines and therapeutics against potential agents of terrorism, address critical public health needs and opportunities for emerging and re-emerging infectious diseases.
Under the CRID contract, EMMES currently provides statistical, data management and operational support of clinical trials vaccines and treatment for many diseases, including anthrax, aspergillosis, cytomegalovirus, dengue, E.coli, Haemophilus influenzae, group B streptococcus, herpes, hepatitis C, HPV, influenza (seasonal, H1N1, and avian), leprosy, malaria, methicillin-resistant Staphylococcus aureus, plague, pneumonia, rotavirus, schistosomiasis, shigella, smallpox, syphilis, typhoid, tularemia, and varicella.